News
Through innovation, cost discipline, legal action, and competitive pricing, Novo Nordisk has reasserted its leadership in the GLP-1 market. With a robust pipeline and global expansion, NVO is poised ...
GLP-1 drugs for diabetes and weight loss may influence patients’ cancer risk, usually lowering it but sometimes possibly ...
The only GLP-1 medication that is FDA-approved to treat sleep apnea is Zepbound; it likely does this by lowering your weight. "If you are not overweight, medications like semaglutide and ...
Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...
The FDA clearance sets Novo’s medicine up a market battle with Madrigal Pharmaceuticals’ fast-selling Rezdiffra.
24/7 Wall St. on MSN2d
Eli Lilly Ranks Among Top Large-Cap Performers as GLP-1 Drug Sales Exceed Billions
Eli Lilly is one of the top growing stocks at the moment. Learn the reasons why this might be a stock to consider.
At a time when shedding pounds may be just a shot away, WeightWatchers is returning to its roots and its community to chart a ...
As Eli Lilly and Novo Nordisk have been battling it out to gain market share of the growing GLP-1 weight loss market, one ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback